乳腺多参数磁共振成像结合机器学习对乳腺癌新辅助化疗早期疗效预测及生存结局的影响
这项经机构审查委员会批准的前瞻性研究纳入38例拟行新辅助化疗的乳腺癌女性,在化疗前及2周期后行3T乳腺多参数MRI(动态对比增强、扩散加权成像、T2加权成像),提取23个特征并用8种分类器进行机器学习分析。以病理残余肿瘤负荷分级(RCB 0为病理完全缓解)、无复发生存和疾病特异性生存为参考标准,XGBoost预测RCB分级AUC为0.86、预测疾病特异性生存AUC为0.92,逻辑回归预测无复发生存AUC为0.83。作者认为乳腺多参数MRI结合机器学习可高精度早期预测病理完全缓解及生存结局,可能为治疗决策提供有价值的预测信息。
要点
- 乳腺多参数MRI结合机器学习可早期预测新辅助化疗后病理完全缓解,XGBoost的AUC为0.86。
- 预测疾病特异性生存以XGBoost表现最佳,AUC为0.92;预测无复发生存以逻辑回归最佳,AUC为0.83。
- 预测病理完全缓解最重要的特征包括病灶大小变化、完全退缩模式、DCE的平均通过时间、DWI的最小ADC及T2加权成像的瘤周水肿。
核心结论
- 乳腺多参数MRI结合机器学习能够以高准确度早期预测乳腺癌患者新辅助化疗后的病理完全缓解及生存结局,因此可能提供有价值的预测信息以指导治疗决策。
研究设计与样本
- 经机构审查委员会批准的前瞻性研究,纳入38例拟行新辅助化疗的乳腺癌女性(中位年龄46.5岁,范围25-70岁),在化疗前及2周期后行3T乳腺多参数MRI(动态对比增强、扩散加权成像、T2加权成像)。
关键影像表现/征象
- 每例病灶提取23个特征,包括按BI-RADS判读的T2加权及DCE-MRI定性特征、定量药代动力学DCE特征(平均血浆流量、容积分布、平均通过时间)及DWI的表观扩散系数值。
- 预测残余肿瘤负荷分级最重要的特征为DCE-MRI上的病灶大小变化、完全退缩模式和平均通过时间,DWI的最小ADC值,以及T2加权成像上的瘤周水肿。
- 预测无复发生存最重要的特征为容积分布、平均血浆流量和平均通过时间,DCE-MRI病灶大小,以及DWI的最小、最大和平均ADC值。
- 预测疾病特异性生存最重要的特征为DCE-MRI上的病灶大小、容积分布和平均血浆流量,以及DWI的最大ADC值。
诊断标准与关键数值
- 以病理残余肿瘤负荷分级为参考标准(RCB 0定义为病理完全缓解),XGBoost分类器预测RCB分级的AUC为0.86。
- 以疾病特异性生存为参考标准,XGBoost分类器预测疾病特异性生存的AUC为0.92。
- 以无复发生存为参考标准,逻辑回归分类器预测无复发生存的AUC为0.83。
- 采用递归特征消除评估分类准确度(以受试者工作特征曲线下面积AUC表示),并使用4折交叉验证以克服过拟合。
临床应用与阅片要点
- 作者认为乳腺多参数MRI结合机器学习可高精度早期预测新辅助化疗的病理完全缓解及生存结局,因此可能提供有价值的预测信息以指导治疗决策。
- XGBoost分类器与其他分类器相比表现最稳定且准确度高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to assess the potential of machine learning with multiparametric magnetic resonance imaging (mpMRI) for the early prediction of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) and of survival outcomes in breast cancer patients.
MATERIALS AND METHODS: This institutional review board-approved prospective study included 38 women (median age, 46.5 years; range, 25-70 years) with breast cancer who were scheduled for NAC and underwent mpMRI of the breast at 3 T with dynamic contrast-enhanced (DCE), diffusion-weighted imaging (DWI), and T2-weighted imaging before and after 2 cycles of NAC. For each lesion, 23 features were extracted: qualitative T2-weighted and DCE-MRI features according to BI-RADS (Breast Imaging Reporting and Data System), quantitative pharmacokinetic DCE features (mean plasma flow, volume distribution, mean transit time), and DWI apparent diffusion coefficient (ADC) values. To apply machine learning to mpMRI, 8 classifiers including linear support vector machine, linear discriminant analysis, logistic regression, random forests, stochastic gradient descent, decision tree, adaptive boosting, and extreme gradient boosting (XGBoost) were used to rank the features. Histopathologic residual cancer burden (RCB) class (with RCB 0 being a pCR), recurrence-free survival (RFS), and disease-specific survival (DSS) were used as the standards of reference. Classification accuracy with area under the receiving operating characteristic curve (AUC) was assessed using all the extracted qualitative and quantitative features for pCR as defined by RCB class, RFS, and DSS using recursive feature elimination. To overcome overfitting, 4-fold cross-validation was used.
RESULTS: Machine learning with mpMRI achieved stable performance as shown by mean classification accuracies for the prediction of RCB class (AUC, 0.86) and DSS (AUC, 0.92) based on XGBoost and the prediction of RFS (AUC, 0.83) with logistic regression. The XGBoost classifier achieved the most stable performance with high accuracies compared with other classifiers. The most relevant features for the prediction of RCB class were as follows: changes in lesion size, complete pattern of shrinkage, and mean transit time on DCE-MRI; minimum ADC on DWI; and peritumoral edema on T2-weighted imaging. The most relevant features for prediction of RFS were as follows: volume distribution, mean plasma flow, and mean transit time; DCE-MRI lesion size; minimum, maximum, and mean ADC with DWI. The most relevant features for prediction of DSS were as follows: lesion size, volume distribution, and mean plasma flow on DCE-MRI, and maximum ADC with DWI.
CONCLUSIONS: Machine learning with mpMRI of the breast enables early prediction of pCR to NAC as well as survival outcomes in breast cancer patients with high accuracy and thus may provide valuable predictive information to guide treatment decisions.
引用
- Tahmassebi A, Wengert GJ, Helbich TH, et al. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients. Invest Radiol. 2019. PMID: 30358693. doi:10.1097/RLI.0000000000000518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。